VAR-101 / Windtree Therap - LARVOL DELTA

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing (GlobeNewswire) - "Windtree Therapeutics...announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc. ('Varian') to acquire certain of its assets, including a proprietary atypical protein kinase C iota inhibitor (aPKCi). The Company also completed a $1.5 million convertible note bridge financing. The acquired Varian asset platform is a novel, potential high-potency, specific, aPKCi with possible broad use in oncology as well as certain rare malignant diseases. The asset platform includes two formulations: VAR-101 (topical) and VAR-102 (oral)."

Licensing / partnership • Oncology

Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals (GlobeNewswire) - "Biodexa Pharmaceuticals PLC...is pleased to announce that it has signed non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, Inc. ('VarianBio'), a private US precision oncology company developing novel therapeutics for the treatment of cancer....Under the non-binding letter of intent, VarianBio will merge into an acquisition subsidiary of the Company and it is proposed that VarianBio equity and debt holders (together,'VarianBio Securityholders') will receive 10MM of the Company’s American Depositary Shares ('ADSs'), at close as initial consideration....In addition, pursuant to the non-binding heads of terms, the Company plans to raise not less than US$7.0MM, net of expenses, which will be used to fund VAR-101 through its Phase I proof-of-concept study that VAR-101 is targeting to commence in the first quarter of 2024."

Financing • M&A • New P1 trial • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor

HEALTHTECH SOLUTIONS, INC. ANNOUNCES CONTRACT TO ACQUIRE VARIAN BIOPHARMACEUTICALS, A PRECISION ONCOLOGY COMPANY (GlobeNewswire) - “Healthtech Solutions…announces that it has entered into an agreement to acquire a wholly-owned subsidiary, Healthtech Oncology, Inc., which will own a 100% interest in Varian Biopharmaceuticals…‘Varian Bio has the support of leading oncology physicians and scientific institutions both in the US and abroad, and aPKCi is a unique protein kinase target whose inhibition could have a significant impact in a broad range of tumor types. We look forward to the opportunity to collaborate with the Healthtech Solutions team.”

M&A • Basal Cell Carcinoma • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Skin Cancer • Solid Tumor